在心力衰竭患者中使用β-阻塞剂,在急性减补心力衰竭住院期间减少排气分数
Matthew T Brennan1, Khaled M Harmouch2, Jawad Basit3
1Wayne State University School of Medicine, Detroit, MI.
Ochsner journal
|September 16, 2024
概括
β阻塞剂改善了心力衰竭患者的心脏衰竭的结果,减少了喷射分数. 根据指导方针的使用,包括在稳定患者中开始使用,可以减少急性不补偿性心力衰竭的死亡率和再住院.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 每年,急性不补偿性心力衰竭导致美国超过100万例住院治疗.
- β阻塞剂对于心力衰竭与减少喷射率至关重要,但在住院期间使用它们是不理想的.
- 进行了证据审查和指导方针分析,以澄清这种情况下的β-阻断剂处方.
研究的目的:
- 分析现有的证据和关于在急性不补偿性心力衰竭中使用β-阻断剂的指导方针.
- 确定在住院患者中启动或继续β-阻断剂治疗的最佳条件.
- 为临床医生提供决策框架.
主要方法:
- 在PubMed中搜索 (2004-2024) "β阻塞剂"和"急性不补偿性心力衰竭".
- 包括关于在心力衰竭中使用β-阻塞剂的研究,其中包括心力衰竭和减少喷射率的研究.
- 专业社会对beta阻断剂管理的建议的汇编.
主要成果:
- 在心力衰竭患者中维持β抑制剂治疗,减少喷射分数,降低死亡率和再住院率.
- 取消β抑制剂会增加住院和短期死亡率.
- 一个基于指导方针的流程图被开发为指导临床决策.
结论:
- 以指导方针指导的β抑制剂治疗改善了心力衰竭患者的治疗结果,心力衰竭患者的心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭患者心脏衰竭
- 建议在血液动力学稳定的患者中开始低剂量β-阻塞剂.
- 开发的流程图有助于医生优化β抑制剂的使用,以获得更好的患者结果.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
321
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
321
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
543
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
543
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
01:22Heart Failure Drugs: Diuretics
350
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
350
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
420
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
420
01:28Antihypertensive Drugs: Types of β-Blockers
603
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
603